0001127602-23-029515.txt : 20231212 0001127602-23-029515.hdr.sgml : 20231212 20231212204620 ACCESSION NUMBER: 0001127602-23-029515 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231208 FILED AS OF DATE: 20231212 DATE AS OF CHANGE: 20231212 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LAURENCIN CATO T CENTRAL INDEX KEY: 0001444810 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35299 FILM NUMBER: 231482790 MAIL ADDRESS: STREET 1: C/O UNIVERSITY OF CONNECTICUT STREET 2: 263 FARMINGTON AVENUE CITY: FARMINGTON STATE: CT ZIP: 06030-3800 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Alkermes plc. CENTRAL INDEX KEY: 0001520262 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 981007018 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: CONNAUGHT HOUSE STREET 2: 1 BURLINGTON ROAD CITY: DUBLIN 4 STATE: L2 ZIP: 00000 BUSINESS PHONE: 00-353-1-772-8000 MAIL ADDRESS: STREET 1: CONNAUGHT HOUSE STREET 2: 1 BURLINGTON ROAD CITY: DUBLIN 4 STATE: L2 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: ANTLER SCIENCE TWO PLC DATE OF NAME CHANGE: 20110804 FORMER COMPANY: FORMER CONFORMED NAME: Antler Science Two Ltd DATE OF NAME CHANGE: 20110509 4 1 form4.xml PRIMARY DOCUMENT X0508 4 2023-12-08 0001520262 Alkermes plc. ALKS 0001444810 LAURENCIN CATO T CONNAUGHT HOUSE 1 BURLINGTON ROAD DUBLIN 4 Ireland 1 0 Ordinary Shares 2023-12-08 4 M 0 4163 A 16169 D Ordinary Shares 2023-12-08 4 F 0 1000 25.86 D 15169 D Non Qualified Stock Option (Right to Buy) 22.52 2023-11-17 5 J 0 E 112 22.52 A 2031-12-08 Ordinary Shares 112 5712 D Non Qualified Stock Option (Right to Buy) 22.52 2023-11-17 5 J 0 E 422 22.52 A 2031-12-08 Ordinary Shares 422 21523 D Non Qualified Stock Option (Right to Buy) 30.863 2023-11-17 5 J 0 E 231 30.863 A 2032-07-07 Ordinary Shares 231 11785 D Non Qualified Stock Option (Right to Buy) 30.716 2023-11-17 5 J 0 E 254 30.716 A 2024-06-29 2033-06-29 Ordinary Shares 254 12986 D Restricted Stock Unit Award 2023-11-17 5 J 0 E 119 A 2024-06-29 Ordinary Shares 119 6104 D Restricted Stock Unit Award 2023-11-17 5 J 0 E 163 A Ordinary Shares 163 8326 D Restricted Stock Unit Award 2023-12-08 4 M 0 4163 D Ordinary Shares 4163 4163 D Each restricted stock unit represents a contingent right to receive one ordinary share. Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. This award is fully vested in accordance with its terms. Shares subject to the stock option award vest in three equal annual installments commencing on 12/8/2022. These options are fully vested in accordance with their terms. Shares subject to the stock option award vest and become exercisable in full on 6/29/2024. Shares subject to the restricted stock unit award vest in full on 6/29/2024. Shares subject to the restricted stock unit award vest in three annual installments commencing on 12/8/2022. /s/ Shantale Greenson, attorney-in-fact for Cato T. Laurencin 2023-12-12